Effects of oral α-lipoic acid administration on body weight in overweight or obese subjects

a crossover randomized, double-blind, placebo-controlled trial

Nong Li, Weili Yan, Xiaojuan Hu, Yongdi Huang, Fugang Wang, Weiguo Zhang, Qian Wang, Xiaoling Wang, Kehong Sun

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Objective: Alpha-lipoic acid (ALA) has shown beneficial properties on diabetes and obesity. The aim of this study was to examine the effects of oral ALA on body weight in subjects with overweight or obese. Design: Single-centre, randomized, double-blind, crossover controlled study. Participants: A total of 166 subjects of Chinese Han ethnicity with a BMI ≥25 kg/m 2 were screened and 103 subjects fulfilled the study requirements, in terms of informed consent and participation to the study. Measurements: The subjects were randomized (1:1) to receive either ALA (1200 mg/day) or placebo treatment in a crossover design for 8 weeks. The primary end-point was the change in body weight. The secondary end-points were the changes in waist circumference, BMI, lipid profile, plasma leptin levels and the adverse events that occurred following ALA treatment. Results: The changes in the body weight and waist circumference noted in the ALA group were significantly different compared to the placebo group as demonstrated by mixed model statistical analysis (both P < 0·05). No real weight reduction was seen in the ALA group, and no significant differences were noted as regards cholesterol levels, triglyceride levels, high-density lipoprotein cholesterol levels and adverse events between the two groups. The administration of ALA was well tolerated, and no serious adverse events were noted. Conclusions: Oral administration of ALA (1200 mg/day) for 8 weeks induced mild weight loss accompanied by a reduction in waist circumference.

Original languageEnglish (US)
Pages (from-to)680-687
Number of pages8
JournalClinical Endocrinology
Volume86
Issue number5
DOIs
StatePublished - May 1 2017

Fingerprint

Thioctic Acid
Placebos
Body Weight
Waist Circumference
Body Weight Changes
Cross-Over Studies
Weight Loss
Statistical Models
Leptin
Informed Consent
HDL Cholesterol
Oral Administration
Triglycerides
Obesity
Cholesterol
Lipids
Therapeutics

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Effects of oral α-lipoic acid administration on body weight in overweight or obese subjects : a crossover randomized, double-blind, placebo-controlled trial. / Li, Nong; Yan, Weili; Hu, Xiaojuan; Huang, Yongdi; Wang, Fugang; Zhang, Weiguo; Wang, Qian; Wang, Xiaoling; Sun, Kehong.

In: Clinical Endocrinology, Vol. 86, No. 5, 01.05.2017, p. 680-687.

Research output: Contribution to journalArticle

Li, Nong ; Yan, Weili ; Hu, Xiaojuan ; Huang, Yongdi ; Wang, Fugang ; Zhang, Weiguo ; Wang, Qian ; Wang, Xiaoling ; Sun, Kehong. / Effects of oral α-lipoic acid administration on body weight in overweight or obese subjects : a crossover randomized, double-blind, placebo-controlled trial. In: Clinical Endocrinology. 2017 ; Vol. 86, No. 5. pp. 680-687.
@article{830be47c9d6a45a5b8e4c4bc605a9fc4,
title = "Effects of oral α-lipoic acid administration on body weight in overweight or obese subjects: a crossover randomized, double-blind, placebo-controlled trial",
abstract = "Objective: Alpha-lipoic acid (ALA) has shown beneficial properties on diabetes and obesity. The aim of this study was to examine the effects of oral ALA on body weight in subjects with overweight or obese. Design: Single-centre, randomized, double-blind, crossover controlled study. Participants: A total of 166 subjects of Chinese Han ethnicity with a BMI ≥25 kg/m 2 were screened and 103 subjects fulfilled the study requirements, in terms of informed consent and participation to the study. Measurements: The subjects were randomized (1:1) to receive either ALA (1200 mg/day) or placebo treatment in a crossover design for 8 weeks. The primary end-point was the change in body weight. The secondary end-points were the changes in waist circumference, BMI, lipid profile, plasma leptin levels and the adverse events that occurred following ALA treatment. Results: The changes in the body weight and waist circumference noted in the ALA group were significantly different compared to the placebo group as demonstrated by mixed model statistical analysis (both P < 0·05). No real weight reduction was seen in the ALA group, and no significant differences were noted as regards cholesterol levels, triglyceride levels, high-density lipoprotein cholesterol levels and adverse events between the two groups. The administration of ALA was well tolerated, and no serious adverse events were noted. Conclusions: Oral administration of ALA (1200 mg/day) for 8 weeks induced mild weight loss accompanied by a reduction in waist circumference.",
author = "Nong Li and Weili Yan and Xiaojuan Hu and Yongdi Huang and Fugang Wang and Weiguo Zhang and Qian Wang and Xiaoling Wang and Kehong Sun",
year = "2017",
month = "5",
day = "1",
doi = "10.1111/cen.13303",
language = "English (US)",
volume = "86",
pages = "680--687",
journal = "Clinical Endocrinology",
issn = "0300-0664",
publisher = "Wiley-Blackwell",
number = "5",

}

TY - JOUR

T1 - Effects of oral α-lipoic acid administration on body weight in overweight or obese subjects

T2 - a crossover randomized, double-blind, placebo-controlled trial

AU - Li, Nong

AU - Yan, Weili

AU - Hu, Xiaojuan

AU - Huang, Yongdi

AU - Wang, Fugang

AU - Zhang, Weiguo

AU - Wang, Qian

AU - Wang, Xiaoling

AU - Sun, Kehong

PY - 2017/5/1

Y1 - 2017/5/1

N2 - Objective: Alpha-lipoic acid (ALA) has shown beneficial properties on diabetes and obesity. The aim of this study was to examine the effects of oral ALA on body weight in subjects with overweight or obese. Design: Single-centre, randomized, double-blind, crossover controlled study. Participants: A total of 166 subjects of Chinese Han ethnicity with a BMI ≥25 kg/m 2 were screened and 103 subjects fulfilled the study requirements, in terms of informed consent and participation to the study. Measurements: The subjects were randomized (1:1) to receive either ALA (1200 mg/day) or placebo treatment in a crossover design for 8 weeks. The primary end-point was the change in body weight. The secondary end-points were the changes in waist circumference, BMI, lipid profile, plasma leptin levels and the adverse events that occurred following ALA treatment. Results: The changes in the body weight and waist circumference noted in the ALA group were significantly different compared to the placebo group as demonstrated by mixed model statistical analysis (both P < 0·05). No real weight reduction was seen in the ALA group, and no significant differences were noted as regards cholesterol levels, triglyceride levels, high-density lipoprotein cholesterol levels and adverse events between the two groups. The administration of ALA was well tolerated, and no serious adverse events were noted. Conclusions: Oral administration of ALA (1200 mg/day) for 8 weeks induced mild weight loss accompanied by a reduction in waist circumference.

AB - Objective: Alpha-lipoic acid (ALA) has shown beneficial properties on diabetes and obesity. The aim of this study was to examine the effects of oral ALA on body weight in subjects with overweight or obese. Design: Single-centre, randomized, double-blind, crossover controlled study. Participants: A total of 166 subjects of Chinese Han ethnicity with a BMI ≥25 kg/m 2 were screened and 103 subjects fulfilled the study requirements, in terms of informed consent and participation to the study. Measurements: The subjects were randomized (1:1) to receive either ALA (1200 mg/day) or placebo treatment in a crossover design for 8 weeks. The primary end-point was the change in body weight. The secondary end-points were the changes in waist circumference, BMI, lipid profile, plasma leptin levels and the adverse events that occurred following ALA treatment. Results: The changes in the body weight and waist circumference noted in the ALA group were significantly different compared to the placebo group as demonstrated by mixed model statistical analysis (both P < 0·05). No real weight reduction was seen in the ALA group, and no significant differences were noted as regards cholesterol levels, triglyceride levels, high-density lipoprotein cholesterol levels and adverse events between the two groups. The administration of ALA was well tolerated, and no serious adverse events were noted. Conclusions: Oral administration of ALA (1200 mg/day) for 8 weeks induced mild weight loss accompanied by a reduction in waist circumference.

UR - http://www.scopus.com/inward/record.url?scp=85013859565&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85013859565&partnerID=8YFLogxK

U2 - 10.1111/cen.13303

DO - 10.1111/cen.13303

M3 - Article

VL - 86

SP - 680

EP - 687

JO - Clinical Endocrinology

JF - Clinical Endocrinology

SN - 0300-0664

IS - 5

ER -